抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响

doi:10.3969/j.issn.1006-7795.2018.06.004

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (6): 810-814.doi: 10.3969/j.issn.1006-7795.2018.06.004

抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响

耿明凡¹, 高方媛², 李玉鑫², 张群², 刘尧², 王宪波²

1. 首都医科大学密云教学医院中医科, 北京 101500;
2. 首都医科大学附属北京地坛医院中西医结合中心, 北京 100015

收稿日期:2018-09-20 出版日期:2018-11-21 发布日期:2018-12-19
通讯作者: 王宪波 E-mail:junqinhe@sina.com
基金资助:
国家自然科学基金（81503607），北京市医院管理局临床医学发展专项（ZYLX201510），北京市医院管理局"登峰"计划专项（DFL20151301）。

Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B

Geng Mingfan¹, Gao Fangyuan², Li Yuxin², Zhang Qun², Liu Yao², Wang Xianbo²

1. Department of Traditional Chinese Medicine, Miyun Education Hospital, Capital Medical University, Beijing 101500, China;
2. The Center of Integrated Traditional and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Received:2018-09-20 Online:2018-11-21 Published:2018-12-19
Supported by:
This study was supported by National Natural Science Foundation of China(81503607),Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(ZYLX201510),Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20151301).

摘要/Abstract

摘要： 目的探讨抗病毒基础上联合中医药治疗对乙型肝炎e抗原（hepatitis B e antigen，HBeAg）阳性的慢性乙型肝炎患者HBeAg血清转换率的影响。方法将符合纳入标准的679名HBeAg阳性慢性乙型肝炎的患者，根据是否联合应用中医药治疗分为抗病毒西药组（209例）和中西药联合组（470例），观察治疗1年后 HBeAg血清学转换率，分层分析联合治疗的优势人群。结果治疗1年后，抗病毒西药组和中西药联合组HBeAg血清学转换率分别为11.5%和12.8%（P=0.66）；应用课题组前期建立的评分模型分层分析显示，评分0~1分的患者，抗病毒西药组和中西药联合组HBeAg血清学转换率分别为2.6%和8.1%（P=0.04）。结论抗病毒基础上联合中医药治疗能够提高评分为0~1分的慢性乙型肝炎患者HBeAg血清学转换率。

关键词: 慢性乙型肝炎, 慢性乙型肝炎e抗原血清学转换, 抗病毒治疗, 评分模型, 中医药治疗, 联合治疗

Abstract: Objective To investigate the effect of antivirals therapy combined with traditional Chinese medicine therapy on hepatitis B e antigen (HBeAg) seroconversion rate in patients with HBeAg-positive chronic hepatitis B. Methods The 679 HBeAg-positive chronic hepatitis B patients who met the inclusion criteria were divided into the antiviral western medicine group (209 patients) and the Chinese and western medicine combination group (470 patients) according to whether or not they were treated with traditional Chinese medicine. The HBeAg seroconversion rate was observed after 1 year of treatment, and stratified sampling was applied to identify the dominant population of combined therapy. Results After 1 year of the treatment, the seroconversion rate of HBeAg in the antiviral western medicine group and the combined group was 11.5% and 12.8%, respectively, with P=0.66. The patients were scored with the scoring model that our group established in the early stage. For those patients with a score of 0-1 in the antiviral western medicine group and combined therapy group,HBeAg conversion rates were 2.6% and 8.1%, respectively, with P=0.04. Conclusion On the basis of antiviral treatment, combined Chinese medicine treatment can improve the HBeAg seroconversion rate of chronic hepatitis B patients with a score of 0-1.

Key words: chronic hepatitis B, hepatitis B e antigen seroconversion, antiviral therapy, scoring model, Chinese medicine treatment, combination therapy

中图分类号:

R575.1

耿明凡, 高方媛, 李玉鑫, 张群, 刘尧, 王宪波. 抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响[J]. 首都医科大学学报, 2018, 39(6): 810-814.

Geng Mingfan, Gao Fangyuan, Li Yuxin, Zhang Qun, Liu Yao, Wang Xianbo. Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B[J]. Journal of Capital Medical University, 2018, 39(6): 810-814.

参考文献

[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):383-403.
[2] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志,2015,9(5):1-17.
[3] Piratvisuth T. Reviews for APASL guidelines:immunomodulator therapy of chronic hepatitis B[J].Hepatol Int,2008, 2(2):140-146.
[4] Lau G K, Wang F S.Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion:a need for more translational study[J].J Hepatol,2012, 56(4):753-755.
[5] Liaw Y F, Kao J H, Piratvisuth T, et al. Asian-pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J]. Hepatol Int,2012, 6(3):531-561.
[6] Fattovich G, Brollo L, Giustina G,et al.Natural history and prognostic factors for chronic hepatitis type B[J].Gut,1991,32(3):294-298.
[7] Lin B, Ha N B, Liu A, et al.Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos (t) ides in routine practice[J].J Gastroenterol Hepatol,2013,28(5):855-860.
[8] Fried M W, Piratvisuth T, Lau G K, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology, 2008, 47(2):428-434.
[9] Li X, Wang Y, Han D, et al. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B[J]. Hepatol Res, 2014, 44(2):187-193.
[10] Chi H, Bömmel F V, Buti M, et al. P0661:Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count:Results from a large european multi-center study[J]. J Hepatol, 2015, 62(422):S568.
[11] Wang J, Du L Y, Zhu X, et al. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks[J]. Indian J Med Microbiol, 2015,33 Suppl:20-25.
[12] Huang R, Yang C C, Liu Y, et al. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients[J].World J Gastroenterol,2015,21(34):9957-9965.
[13] Geng M, Li Y X, Gao F Y, et al. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogues:real-world clinical practice[J]. Int J Infect Dis, 2017, 62:18-25.
[14] Hui C K, Leung N, Shek T W, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients[J]. Hepatology, 2007, 46(3):690-698.
[15] 王传敏, 柯昌征, 张银华,等. 扶正化瘀胶囊联合阿德福韦酯治疗慢性乙型肝炎的疗效及对免疫功能和肝功能的影响[J]. 现代中西医结合杂志, 2015,24(15):1618-1620.
[16] 杨琴, 马臻. 复方鳖甲软肝片联合恩替卡韦治疗对慢性乙肝患者肝纤维化进程及免疫应答状态的影响[J]. 海南医学院学报, 2018,24(5):593-596.
[17] 张俊婷, 安和兵. 阿德福韦酯联合九味肝泰治疗对儿童慢性乙型肝炎患者T细胞亚群及肝纤维化指标的影响[J]. 安徽医学, 2018(5):537-540.
[18] 仇君, 何荣芬, 高亮. 茵栀黄口服液在免疫性肝损伤中的作用研究[J]. 中国药房, 2010,21(27):2510-2512.
[19] 赵长青, 徐列明. 扶正化瘀胶囊/片治疗肝纤维化和肝硬化的临床研究进展[J]. 世界中医药, 2014,9(5):561-567.
[20] Deng X, Liang J, Liu Z W, et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis[J]. Chin J Integr Med, 2013, 19(4):289-296.
[21] 段雪琳, 黎桂玉, 李树民,等. 复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析[J]. 中国医院药学杂志, 2015, 35(19):1762-1765.
[22] 夏晖, 张宁, 周双男,等. 复方鳖甲软肝片抗肝纤维化研究进展[J]. 医药导报, 2013, 32(4):500-503.

抗病毒药物联合中医药治疗对慢性乙型肝炎e抗原血清转化率的影响

Antivirals therapy combined with traditional Chinese medicine effects on HBeAg seroconversion rate in patients with chronic hepatitis B

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	许志亮. 非手术根管再治疗-根尖手术联合治疗难治性根尖周炎[J]. 首都医科大学学报, 2015, 36(3): 478-482.
[2]	刘晨. 丙型肝炎患者抗病毒治疗依从性影响因素和护理对策[J]. 首都医科大学学报, 2015, 36(3): 501-504.
[3]	欧晓娟;王晓明;尤红;贾继东;王宇;段维佳;李忆梅;李佳;王宝恩. 阿德福韦酯（阿迪仙）治疗慢性乙型肝炎患者4年临床疗效观察[J]. 首都医科大学学报, 2010, 31(5): 570-572.
[4]	杨烨;陈景寿;欧晓娟;贾继东;尤红. 核苷（酸）类似物治疗失代偿期乙肝肝硬化的随访研究[J]. 首都医科大学学报, 2010, 31(5): 573-577.
[5]	任江波;王宇;李红艺;孙淑杰;马红;贾继东. 阿德福韦酯治疗替比夫定耐药慢性乙型肝炎疗效初探[J]. 首都医科大学学报, 2010, 31(5): 566-569.
[6]	尤红;吴晓宁;王倩怡;吴鹏;丛瑞;杨爱婷;欧晓娟;马红;张福奎;王宝恩;贾继东. 恩替卡韦对慢性乙型肝炎、肝硬化代偿期和失代偿期的2年抗病毒疗效比较[J]. 首都医科大学学报, 2010, 31(5): 563-565.
[7]	陈乐天;段婷;宋淑菊. 改善病情抗风湿药联合治疗类风湿性关节炎的疗效及安全性比较[J]. 首都医科大学学报, 2009, 30(4): 538-541.
[8]	张海萍;闫惠平;冯霞;檀玉芬;刘妍;李伟华;马冬梅;赵艳;崔丹. 乙肝病毒感染者血清抗核抗体特征及其临床相关性[J]. 首都医科大学学报, 2007, 28(2): 154-157.
[9]	陈新月;于岩岩;张文瑾;徐道振;马丽娜;黄云丽;沈成利;斯崇文. 慢性乙型肝炎抗病毒治疗疗效及因素研究[J]. 首都医科大学学报, 2006, 27(2): 166-170.
[10]	黄雁翔;陈新月;李卓;刘林华;陈杰. MxA启动子-88的基因多态性与干扰素治疗慢性乙型肝炎疗效的关系[J]. 首都医科大学学报, 2006, 27(2): 183-186.
[11]	张文中. 干扰素治疗慢性乙型肝炎的随访研究[J]. 首都医科大学学报, 2002, 23(3): 229-231.
[12]	陈新月;闵佳;李俊红;辛咏梅;汪俊韬. 泛昔洛韦治疗慢性乙型肝炎的近期疗效[J]. 首都医科大学学报, 2002, 23(2): 145-147.
[13]	宋小平;陈祖贵;闵福援;冷强;孙丽梅;吴昊;林秀玉;汪俊韬. 慢性丙型肝炎患者外周血T淋巴细胞亚群的检测[J]. 首都医科大学学报, 1994, 15(2): 119-122.